Drug Trial Radar · NCT06314373
A Study for HSK39775 in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
243
Planned (sponsor's estimate)
Start
Mar 7, 2024
Primary completion
Feb 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Xizang Haisco Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
HSK39775 MonotherapyDrug
HSK39775 will be administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE/SAETime frame: From time of informed consent to 28 days post last dose or start of other anti-cancer therapies
- DLTTime frame: From the start of first dose to the end of Cycle1(each cycle is 28 days)
- MTD/MADTime frame: From the start of first dose to the end of Cycle1(each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fundan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.